[go: up one dir, main page]

MX2019003890A - Anticuerpos con union reducida a impurezas de proceso. - Google Patents

Anticuerpos con union reducida a impurezas de proceso.

Info

Publication number
MX2019003890A
MX2019003890A MX2019003890A MX2019003890A MX2019003890A MX 2019003890 A MX2019003890 A MX 2019003890A MX 2019003890 A MX2019003890 A MX 2019003890A MX 2019003890 A MX2019003890 A MX 2019003890A MX 2019003890 A MX2019003890 A MX 2019003890A
Authority
MX
Mexico
Prior art keywords
antibodies
variant
process impurities
binding
reduced binding
Prior art date
Application number
MX2019003890A
Other languages
English (en)
Inventor
Uden Mark
John Kenneth Lewis William
Bosteels Hella
Chen Shugui
Farrow Kayeleigh
Kucia-Tran Richard
S Thomson Andrew
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2019003890A publication Critical patent/MX2019003890A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

La presente invención se refiere a anticuerpos variantes y métodos de generación de dichos anticuerpos con un nivel reducido de unión a impurezas de proceso. En particular, la invención describe anticuerpos lgG4 variantes que han sido modificados en la región constante de cadena pesada en uno cualquiera o una combinación de aminoácidos en la región entre los residuos de Kabat 203 y 256, en donde el anticuerpo lgG4 variante tiene un nivel reducido de unión a proteína de célula hospedera (PCH) en comparación con un anticuerpo lgG4 no modificado. La invención también se refiere a composiciones que comprenden dichos anticuerpos IgG4 variante.
MX2019003890A 2016-10-06 2017-10-03 Anticuerpos con union reducida a impurezas de proceso. MX2019003890A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404849P 2016-10-06 2016-10-06
PCT/EP2017/075038 WO2018065389A1 (en) 2016-10-06 2017-10-03 Antibodies with reduced binding to process impurities

Publications (1)

Publication Number Publication Date
MX2019003890A true MX2019003890A (es) 2019-08-12

Family

ID=60143674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003890A MX2019003890A (es) 2016-10-06 2017-10-03 Anticuerpos con union reducida a impurezas de proceso.

Country Status (14)

Country Link
US (1) US11254753B2 (es)
EP (1) EP3523329A1 (es)
JP (1) JP7471819B2 (es)
KR (1) KR20190057083A (es)
CN (1) CN109790216A (es)
AU (1) AU2017338291A1 (es)
BR (1) BR112019004938A2 (es)
CA (1) CA3037264A1 (es)
IL (1) IL265748A (es)
MX (1) MX2019003890A (es)
RU (1) RU2771330C2 (es)
SG (1) SG11201901468SA (es)
TW (1) TW201829453A (es)
WO (1) WO2018065389A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7257335B2 (ja) 2017-05-25 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2021014171A (es) * 2019-05-21 2022-01-04 Regeneron Pharma Metodos para identificar y cuantificar proteinas de la celula huesped.
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
JP2023519602A (ja) * 2020-03-31 2023-05-11 メディミューン，エルエルシー 安定化ＩｇＧ４抗体及びその使用
WO2022155340A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
JP2024530402A (ja) 2021-07-12 2024-08-21 ジェネンテック， インコーポレイテッド 抗体－リパーゼ結合を減少させるための構造
AR128689A1 (es) 2022-03-03 2024-06-05 Univ Yale Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009307728B2 (en) * 2008-10-20 2014-12-11 Abbvie Inc. Antibodies that bind to IL-18 and methods of purifying the same
KR101791430B1 (ko) * 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
EP4331605A3 (en) * 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica

Also Published As

Publication number Publication date
JP7471819B2 (ja) 2024-04-22
RU2771330C2 (ru) 2022-04-29
AU2017338291A1 (en) 2019-03-14
SG11201901468SA (en) 2019-03-28
IL265748A (en) 2019-06-30
US11254753B2 (en) 2022-02-22
KR20190057083A (ko) 2019-05-27
EP3523329A1 (en) 2019-08-14
RU2019106819A (ru) 2020-11-06
CA3037264A1 (en) 2018-04-12
TW201829453A (zh) 2018-08-16
JP2019532957A (ja) 2019-11-14
US20190225708A1 (en) 2019-07-25
RU2019106819A3 (es) 2021-06-04
CN109790216A (zh) 2019-05-21
BR112019004938A2 (pt) 2019-06-25
WO2018065389A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
MX2019003890A (es) Anticuerpos con union reducida a impurezas de proceso.
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
WO2016033225A3 (en) Antibodies, compositions, and uses
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
AU2017286676A8 (en) Purification of multispecific antibodies
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EP4324481A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018031490A3 (en) Anti-ox40 binding proteins
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
WO2018069871A3 (en) Anti-kras binding proteins
MX2017015927A (es) Fragmentos mutantes de proteina ras.
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
EP4273165A3 (en) Interferon beta antibodies and uses thereof
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof